|Place your mouse over each cart item to see full description.
Chemical Name: Isradipine
Dynacirc (Isradipine) is recommended for the treatment of essential hypertension.
Dynacirc (Isradipine) can be administered with or without food. The recommended dosage is 2.5 mg twice a day (i.e. about every 12 hours). Treatment for 3-4 weeks is required for the maximum effect to develop. If blood pressure is not adequately controlled after this period patients may require a dosage of 5 mg twice a day, or if more appropriate, the addition of a low dose of another anti-hypertensive agent i.e. thiazide diuretic or beta-blocker. Exceptionally some patients may require up to 10mg twice a day. Dynacirc (Isradipine) can also be added to an ongoing regimen of other anti-hypertensive agents.
Dynacirc Side Effects:
Clinical studies indicate that Dynacirc (Isradipine) is well tolerated with an overall incidence of adverse events similar to that of placebo when used in doses up to 2.5 mg twice a day. Generally side effects are mild, dose dependent and tend to disappear or decrease in intensity as treatment is continued. Discontinuation of therapy is generally not required. Those side effects mentioned most often are related to the vasodilating properties of Dynacirc (Isradipine): headache, flushing, dizziness, tachycardia and palpitation, and localised peripheral oedema of non-cardiac origin; hypotension is uncommon and there have been no reports of orthostatic hypotension.
Non-specific side effects are rare and include: weight gain, fatigue, abdominal discomfort, and skin rash.
Elevations of serum transaminases have been observed on very rare occasions; these changes were reversible both spontaneously and on following Dynacirc (Isradipine) withdrawal.
As with other dihydropyridines, aggravation of underlying angina has been reported in a small number of individuals especially after starting treatment. This is more likely to happen in patients with symptomatic ischaemic heart disease. Dynacirc (Isradipine) should be discontinued under medical supervision in patients who develop unstable angina.
Patients with a previous allergic reaction to isradipine and other dihydropyridines because of the theoretical risk of cross-reactivity should not use Dynacirc.
Dihydropyridines, including Dynacirc (Isradipine) Tablets, should be discontinued in patients who develop cardiogenic shock. They should also not be used in patients with symptomatic or tight aortic stenosis, and during or within one month of myocardial infarction.
Dihydropyridines including Dynacirc (Isradipine) Tablets should not be used for the prevention of secondary myocardial infarctions and they have not been approved for the treatment of hypertensive crisis.
Dihydropyridines, including Dynacirc (Isradipine) Tablets, should not be used in patients with unstable angina.
All prices are in US dollars.
The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.
Back to Main Drug Information Page